Skip to main content

Market Overview

Medicare Coverage For Natera's Signatera For Pan-Cancer Immunotherapy Monitoring

Share:
Medicare Coverage For Natera's Signatera For Pan-Cancer Immunotherapy Monitoring
  • CMS Molecular Diagnostics Services Program (MolDX) has issued a final local coverage determination (LCD) for pan-cancer immunotherapy monitoring using Natera Inc's (NASDAQ: NTRA) Signatera molecular residual disease (MRD) test. 
  • An accompanying Billing and Coding Article specifies that serial testing with Signatera is now covered for Medicare patients being treated with immunotherapy, regardless of tumor type. 
  • The final LCD for immunotherapy monitoring is the second Medicare LCD covering Signatera (the first was in early-stage colorectal cancer).
  • But it is the first covering Signatera for pan-cancer use in any patient where immunotherapy is indicated.
  • Signatera is a custom-built circulating tumor DNA (ctDNA) test for treatment monitoring and molecular residual disease (MRD) assessment in patients previously diagnosed with cancer. 
  • Price Action: NTRA shares are up 3.70% at $110.96 during the market session on the last check Thursday.
 

Related Articles (NTRA)

View Comments and Join the Discussion!

Posted-In: Briefs DiagnosticsGovernment News Health Care Movers Trading Ideas General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com